A couple of statements from this caught my eye that may have relevance to our mysterious orphan indication.

1) "Beneficial effects (of RVX-208 treatment) were also observed on CVD biomarkers, such as high-sensitivity C-reactive protein, alkaline phosphatase, and components of the complement and coagulation cascades"

2) "Based on its mechanism of action, BET inhibitors such as RVX-208 may have additional utility in indications related to its effects on multiple biologies – for example, chronic kidney disease, Alzheimer’s disease, heart failure, peripheral artery disease and other immune-related disorders."

We know that the RVX team is attending the 15th European Meeting on Complement in Human Disease, Uppsala, Sweden, June 27-30.

Hmmmmm.......